Zydus Hospitals, Ahmedabad Unit is a 550-bed Super multi-specialty regional hospital chain in Ahmedabad, Gujarat. It is the 18th hospital in India to receive the award of global green-OT. Zydus Hospitals, Ahmedabad uses Gemstone Spectral Imaging Technology, a first of its kind in Asia. The hospital is to invest Rs. 1,000 Crore in the state of Gujarat, one of the largest healthcare investments in India. Other units of the chain being Zydus Hospitals at Anand & the newly opened unit at Baroda. Zydus group has a unit in Sitapur as a JV with Suzuki & a medical College too named - Zydus Medical College and Hospital, Dahod. The medical College is a self-financed brown field medical college having Public Private Partnership (PPP) with Government of Gujarat under health policy - 2016. It is managed by Zydus Foundation, Ahmedabad and affiliated to Shri Govind Guru University, Godhra.
Background: Heart failure (HF) is a complex clinical condition requiring resource-intensive management and substantial health expenditure. The adverse economic impact of medical care on patients or financial burden is increasingly recognised as a significant non-clinical entity affecting HF management in low-and middle-income countries (LMIC). We explored the factors associated with Financial Burden (FB) in HF patients in India. Methods: We recruited HF patients from 21 hospitals across India, selected to reflect regional diversity and varying stages of epidemiological transition. Trained personnel collected clinical and economic data using a validated and structured questionnaire. Expenditures were recorded in Indian rupees (INR) and converted to international dollars (INT$). Results: We recruited 1,859 participants. Nearly one-third of participants (30.2%) were women. The mean age was 55.9 (11.3) years, and the mean duration of formal education was 11.3 (3.8) years. Health insurance coverage was reported in one-third (32.2%) of the study population. The average annual out-of-pocket (OOP) expenditure was INR 1,06,566 (INT$ 4,709.10), constituting 92.6% (95% CI: 92.5-92.7) of the total health expenditure. Compared to the previous year, a decline in monthly income was reported by 32.3% of individuals and 36.2% of households. Catastrophic health spending (CHS) and distress financing (DF) were observed in 37.7% (35.5-39.9) and 17.7% (15.9-19.4) of the households, respectively. However, CHS and DF were lower [30.8% (26.2-35.4) and 13.6% (10.2-17.0), respectively] among those with health insurance compared to the uninsured [40.3% (37.6-43.0) and 18.9% (16.7-21.1), respectively]. Conclusion: Seven out of 10 HF patients in India lack financial health protection. OOP expenditures, accounting for over 90% of total health spending, contribute significantly to economic distress in HF patients. Financial burden, affecting more than one-third of HF patients, carries profound implications for individual well-being. Addressing this financial burden, including CHS and DF, is essential for improving clinical outcomes and ensuring health equity.
Background: Brain abscess is a life-threatening intracranial infection, typically caused by contiguous spread (e.g., sinusitis) or hematogenous seeding (e.g., endocarditis), and is more common in males and in developing countries, with peak incidence in the first two decades of life. Symptoms include headache, fever, altered mental status, nausea/vomiting, seizures (25–34%), and focal neurological deficits. It progresses through four stages over 2–4 weeks, culminating in capsule formation. Diagnosis is best achieved with MRI (especially DWI and ¹H-MRS), which differentiates abscesses from tumors, while CT supports localization and monitoring. Treatment involves ≥6 weeks of BBB-penetrating antibiotics and surgery—stereotactic aspiration for abscesses >2.5 cm, or excision for complex cases. Corticosteroids are used cautiously; anticonvulsants may be continued long-term. With prompt combined therapy, cure rates exceed 90%. Close imaging follow-up is essential to detect complications. This study highlights significant variability in presentation, pathology, management, and outcomes among surgical patients. Methods: This prospective study analyzed 17 patients with brain abscess treated surgically at the Department of Neurosurgery, SVP Hospital and SMT. NHL Medical College, Ahmedabad, between January 2022 and August 2025. Inclusion required microbiological/histopathological confirmation of infection, characteristic MRI/CT findings, and lesion resolution with antibiotics; cases due to postoperative complications or meningioencephalitis were excluded. All patients underwent baseline and serial CT scans to evaluate abscess size, wall morphology, and perifocal edema. Abscesses ≥2 cm were managed surgically—predominantly via craniotomy and excision—while those <2 cm received medical therapy alone. Empirical broad-spectrum intravenous antibiotics were initiated immediately, adjusted based on culture and sensitivity, and continued for six weeks. Adjunctive corticosteroids were given under antibiotic cover and tapered over four weeks. Postoperative CT was performed within 24 hours, followed by imaging at 1, 3, and 6 months. Clinical outcomes were assessed using the modified Rankin Scale. The study underscores a standardized, multimodal approach to brain abscess management with favorable outcomes. Results: This prospective study analyzed 17 brain abscess patients (8 males, 9 females; median age 29 years) treated at SVP Hospital, Ahmedabad (Jan 2022–Aug 2025). Most common symptoms were fever/meningeal signs (11), seizures (5), headache (5), and neurological deficits (6). Temporo-parietal location predominated (11 cases); mean abscess size was 4.5 cm. Sixteen underwent craniotomy with excision; one had aspiration. All received 6 weeks of IV antibiotics (adjusted per culture) and a 4-week steroid taper. Causative organisms were identified in 10 cases (Staphylococcus spp., Streptococcus, M. tuberculosis, Aspergillus, hydatid cyst); 6 were culture-negative. Complications included ventriculitis with hydrocephalus (1), managed with ventriculostomy ± VP shunt. At 6 months, 88.23% had good outcomes (mRS 0–2); 2 patients died (one with congenital heart disease and altered sensorium, the other from meningitis/encephalitis). No recurrences occurred. Early diagnosis, surgical excision, and prompt antimicrobial therapy significantly predicted favorable outcomes (p < 0.001). Conclusion: CNS infections remain life-threatening, demanding urgent multimodal care. Pyogenic brain abscesses >2 cm require emergent surgery—usually burr-hole aspiration; craniotomy is reserved for complex cases. Prolonged (≥6 weeks) IV antibiotics prevent relapse. Despite challenges like diagnostic delays and antimicrobial resistance, outcomes have improved with advanced diagnostics, targeted therapy, and neurocritical care. Timely treatment yields excellent recovery. Reducing the global burden requires equitable access, innovation, and a holistic approach spanning prevention to rehabilitation.
BACKGROUND:Iron deficiency anemia (IDA) is a persistent complication in cancer patients and may result from chronic inflammation, poor nutritional intake, and myelosuppressive therapies. Intravenous (IV) iron preparations, such as iron isomaltoside 1000, allow rapid iron repletion. This study evaluated the drug utilization patterns and safety profile of IV iron isomaltoside 1000 in cancer patients with IDA in a real-world setting. METHODS:This retrospective observational study included 100 adult cancer patients diagnosed with IDA who received IV iron isomaltoside 1000 at two participating centers between January 2024 and September 2025. Demographic data, laboratory parameters (hemoglobin, serum ferritin, total iron-binding capacity (TIBC), and transferrin saturation (TSAT)), dosing details, and adverse events (AEs) were recorded. Continuous variables were expressed as mean ± standard deviation (SD), and paired t-tests were used to compare pre- and post-treatment laboratory values. A p-value less than 0.05 was considered statistically significant. RESULTS:The mean age of patients was 49.5 ± 17.9 years, and 51% were female individuals. The mean baseline hemoglobin was 8.8 ± 1.9 g/dL and improved to 11.68 g/dL (p < 0.001) after one month of treatment. Among the 92 patients with paired baseline and one-month follow-up data, serum ferritin increased from 10.24 ng/mL to 133.16 ng/mL and TSAT improved from 13.28% to 21.98% (p < 0.001), while TIBC decreased from 441.62 µg/dL to 278.00 µg/dL (p < 0.001). AEs occurred in 7% of patients, including Fishbane reaction in 6% and mild musculoskeletal pain in 1%; all were mild and self-limiting. CONCLUSION:IV iron isomaltoside 1000 was associated with significant improvement in hematologic parameters and demonstrated a favorable safety profile in cancer patients with IDA. It can be considered a safe and practical option for rapid iron repletion in cancer management.
Abstract Postprandial glucose (PPG) is an important determinant of glycaemic control. Changes in postprandial levels may precede changes in fasting glucose levels, and postprandial hyperglycemia is an independent determinant of diabetic complications. The management of diabetes should aim to achieve overall glycaemic control, addressing both fasting and postprandial hyperglycemia. A multitude of variables, including demographics, differences in diet and lifestyle, and varied physiological factors, have been described which can alter and influence PPG levels. Therefore, inclusion of PPG in management planning is imperative. This can be done by identifying modifiable factors that positively influence PPG levels and adjusting treatment accordingly, made possible by frequent feedback and monitoring of PPG using practical approaches and individualizing the use of available technologies to achieve better overall glycaemic control.